Roche Signs an AI-Based Research Agreement with Sensyne Health

Roche’s Rozlytrek (entrectinib) Receives MHLW’s Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan


  • Roche and Sensyne Health collaborate to apply AI technology for clinical trial designs and will further strengthen Roche’s approach in data and technology-driven personalized healthcare
  • The collaboration will focus on identifying patient’s population in one disease and further assessing and collating anonymized patient data with anonymized EHR data for supporting clinical trial planning
  • In 2019, Sensyne collaborated with Bayer to accelerate the clinical development of new treatments for cardiovascular disorders

Click here to read full press release/ article | Ref: Sensyne Health | Image: Twitter